Cheng, Ying http://orcid.org/0000-0001-9908-597X
He, Yong
Li, Wei
Zhang, He-long
Zhou, Qing
Wang, Buhai
Liu, Chunling
Walding, Andrew
Saggese, Matilde
Huang, Xiangning
Fan, Minhao
Wang, Jia
Ramalingam, Suresh S.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Time to deterioration of patient-reported outcomes in non-small cell lung cancer: exploring different definitions
https://doi.org/10.1007/s11136-022-03088-0
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
https://doi.org/10.1007/s11523-021-00794-6
Funding for this research was provided by:
AstraZeneca
Article History
Accepted: 27 January 2021
First Online: 5 February 2021
Declarations
:
: The study (NCT02296125) was funded by AstraZeneca, Cambridge, UK, the manufacturer of osimertinib. AstraZeneca was involved in the study design; the collection, analysis, and interpretation of data; the writing of this article; and its approval for submission.
: YC, WL, HZ, and CL have no conflicts of interest that are directly relevant to the content of this article. YH has received personal fees from AstraZeneca, Eli Lilly, Pfizer, and Roche for speaker bureau/expert testimony. QZ has received personal honoraria from AstraZeneca and Roche. BW has received personal fees from AstraZeneca, Boehringer Ingelheim, and Roche for advisory/consultancy and speaker bureau/expert testimony and from Eli Lilly for speaker bureau/expert testimony. AW, MS, and XH are employees and shareholders/stockholders of and hold stock options for AstraZeneca. MF received personal fees from AstraZeneca during the conduct of the study and is an employee of AstraZeneca. JW is an employee of AstraZeneca. SSR has received grants and personal fees from Amgen, BMS, Merck, Tesaro, and Takeda; grants from Advaxis and Genmab; grants, personal fees, and non-financial support from AstraZeneca; and personal fees from Genentech and Glaxo Smith Kline, outside the submitted work.
: The study was approved by the institutional review board or independent ethics committee of each study center. The study was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines (as defined by the International Conference on Harmonization), applicable regulatory requirements, and the policy on bioethics and human biologic samples of the study sponsor, AstraZeneca.
: All patients provided written informed consent prior to treatment.
: Not applicable.
: Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described at ExternalRef removed.
: Not applicable.
: YC, WL, AW, and SSR contributed to the conception and design of the study. YH, WL, HZ, QZ, BW, CL, AW, and JW contributed to collection and assembly of data. YH, WL, QZ, CL, AW, MS, XH, MF, JW, and SSR contributed to data analysis and interpretation. All authors critically reviewed and drafted the manuscript, provided final approval, and agreed to be accountable for all aspects of the work.